激酶抑制剂治疗晚期甲状腺髓样癌。
Kinase inhibitors for advanced medullary thyroid carcinoma.
机构信息
Centre de Référence Tumeurs Réfractaires de la Thyroïde, Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris-Sud XI, Villejuif, France.
出版信息
Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):125-9. doi: 10.6061/clinics/2012(sup01)21.
Abstract
The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.
摘要
分子靶向治疗的出现促使人们重新考虑治疗有远处转移的甲状腺髓样癌患者的策略。对于疾病进展的患者，应提供激酶抑制剂治疗。
相似文献
1
Kinase inhibitors for advanced medullary thyroid carcinoma.
Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):125-9. doi: 10.6061/clinics/2012(sup01)21.
2
Vandetanib and the management of advanced medullary thyroid cancer.
Curr Opin Oncol. 2013 Jan;25(1):39-43. doi: 10.1097/CCO.0b013e32835a42b9.
3
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Bull Cancer. 2014 Sep;101(9):891-5. doi: 10.1684/bdc.2014.2022.
4
Vandetanib for the treatment of medullary thyroid cancer.
Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11.
5
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. doi: 10.1210/jc.2009-2461. Epub 2010 Apr 6.
6
Vandetanib for the treatment of medullary thyroid carcinoma.
Ann Pharmacother. 2014 Mar;48(3):387-94. doi: 10.1177/1060028013512791. Epub 2013 Nov 14.
7
Vandetanib: a guide to its use in advanced medullary thyroid cancer.
BioDrugs. 2012 Dec 1;26(6):431-5. doi: 10.1007/BF03261900.
8
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Thyroid. 2021 Mar;31(3):459-469. doi: 10.1089/thy.2020.0206. Epub 2020 Sep 23.
9
The safety of vandetanib for the treatment of thyroid cancer.
Expert Opin Drug Saf. 2016 Aug;15(8):1107-13. doi: 10.1080/14740338.2016.1201060. Epub 2016 Jul 4.
10
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Expert Rev Anticancer Ther. 2016 Nov;16(11):1109-1118. doi: 10.1080/14737140.2016.1238764. Epub 2016 Sep 30.
引用本文的文献
1
Long-term survival outcomes of systemic therapy in patients with isolated and mixed medullary thyroid cancer.
Heliyon. 2024 Jun 26;10(13):e33654. doi: 10.1016/j.heliyon.2024.e33654. eCollection 2024 Jul 15.
2
The Role of the Kinase Inhibitors in Thyroid Cancers.
Pharmaceutics. 2022 May 11;14(5):1040. doi: 10.3390/pharmaceutics14051040.
3
NEOADJUVANT LENVATINIB IN ADVANCED UNRESECTABLE MEDULLARY THYROID CARCINOMA: A CASE REPORT.
AACE Clin Case Rep. 2019 Dec 20;6(2):e73-e78. doi: 10.4158/ACCR-2019-0365. eCollection 2020 Mar-Apr.
4
Volumetric and texture analysis of pretherapeutic F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib.
Endocrine. 2019 Feb;63(2):293-300. doi: 10.1007/s12020-018-1749-3. Epub 2018 Sep 11.
5
ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report.
Diseases. 2018 Apr 10;6(2):25. doi: 10.3390/diseases6020025.
6
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Drug Des Devel Ther. 2016 Feb 29;10:873-84. doi: 10.2147/DDDT.S93459. eCollection 2016.
7
Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.
Hippokratia. 2014 Apr;18(2):130-4.
8
A differential diagnosis of inherited endocrine tumors and their tumor counterparts.
Clinics (Sao Paulo). 2013 Jul;68(7):1039-56. doi: 10.6061/clinics/2013(07)24.
9
Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2.
Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):149-54. doi: 10.6061/clinics/2012(sup01)25.
本文引用的文献
1
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24.
2
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.
3
High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
J Clin Endocrinol Metab. 2011 May;96(5):E863-8. doi: 10.1210/jc.2010-1921. Epub 2011 Feb 16.
4
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Clin Cancer Res. 2010 Nov 1;16(21):5260-8. doi: 10.1158/1078-0432.CCR-10-0994. Epub 2010 Sep 16.
5
Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.
Thyroid. 2010 Aug;20(8):863-71. doi: 10.1089/thy.2009.0417.
6
Medullary carcinoma.
J Natl Compr Canc Netw. 2010 May;8(5):512-30. doi: 10.6004/jnccn.2010.0040.
7
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
J Clin Endocrinol Metab. 2010 Aug;95(8):3758-62. doi: 10.1210/jc.2009-2507. Epub 2010 May 19.
8
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. doi: 10.1210/jc.2009-2461. Epub 2010 Apr 6.
9
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5.
10
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.
Zotero 插件